EUVIMEDEUVIMED entdecken
Crossref

mRNA‐HPV vaccine encoding E6 and E7 improves therapeutic potential for HPV‐mediated cancers via subcutaneous immunization

Seonghyun Lee iD, Hyunho Yoon, Seol Hee Hong, Sung Pil Kwon, Jung Joo Hong, Hye Won Kwak, Hyeong-Jun Park, Soyeon Yoo, Seo-Hyeon Bae, Hyo-Jung Park, Jisun Lee, Yoo-Jin Bang und 27 weitere

Journal of Medical Virology · 2023

DOI: 10.1002/jmv.29309 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Seonghyun Lee und 38 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea. Hauptthemen laut MEDLINE: Papillomavirus Vaccines, Oncogene Proteins, Viral, Papillomavirus Infections, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Korea Health Industry Development Institute, Ministry of Food and Drug Safety, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The E6 and E7 proteins of specific subtypes of human papillomavirus (HPV), including HPV 16 and 18, are highly associated with cervical cancer as they modulate cell cycle regulation. The aim of this study was to investigate the potential antitumor effects of a messenger RNA‐HPV therapeutic vaccine (mHTV) containing nononcogenic E6 and E7 proteins. To achieve this, C57BL/6j mice were injected with the vaccine via both intramuscular and subcutaneous routes, and the resulting effects were evaluated. mHTV immunization markedly induced robust T cell‐mediated immune responses and significantly suppressed tumor growth in both subcutaneous and orthotopic tumor‐implanted mouse model, with a significant infiltration of immune cells into tumor tissues. Tumor retransplantation at day 62 postprimary vaccination completely halted progression in all mHTV‐treated mice. Furthermore, tumor expansion was significantly reduced upon TC‐1 transplantation 160 days after the last immunization. Immunization of rhesus monkeys with mHTV elicited promising immune responses. The immunogenicity of mHTV in nonhuman primates provides strong evidence for clinical application against HPV‐related cancers in humans. All data suggest that mHTV can be used as both a therapeutic and prophylactic vaccine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus VaccinesOncogene Proteins, ViralPapillomavirus InfectionsUterine Cervical NeoplasmsHumansFemaleAnimalsMiceHuman Papillomavirus VirusesRNA, MessengerPapillomavirus E7 ProteinsMice, Inbred C57BLVaccinationImmunization

Stichwörter der Autor:innen

HPVHPV-mediated cancercancer therapytherapeutic mRNAvaccine

Substanzen

Papillomavirus VaccinesOncogene Proteins, ViralRNA, MessengerPapillomavirus E7 Proteins

Autor:innen und Institutionen

  • Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
  • BK21 four Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
  • National Immunotherapy Innovation Center, Hwasun-gun, Jeonnam, South Korea.
  • Department of Pharmacology and Dental Therapeutics, School of Dentistry, Chonnam National University, Gwangju, South Korea.
  • Brain Science Institute, Korea Institute of Science and Technology, Seoul, South Korea.
  • National Primate Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Cheongju, Chungcheongbuk-do, South Korea.

ORCID-Profile: Seonghyun Lee, Jae-Hwan Nam

Förderung

  • Korea Health Industry Development Institute
  • Ministry of Food and Drug Safety
  • National Research Foundation of Korea
  • Korea Centers for Disease Control and Prevention
  • Korea Research Institute of Bioscience and Biotechnology
  • Brain Korea 21 four Program
  • Korea Institute of Science and Technology
  • National Research Council of Science and Technology

Zitieren

APA

Lee, S., Yoon, H., Hong, S. H., Kwon, S. P., Hong, J. J., Kwak, H. W., Park, H. J., Yoo, S., Bae, S. H., Park, H. J., Lee, J., Bang, Y. J., Lee, Y. S., Kim, J. Y., Yoon, S., Roh, G., Cho, Y., Kim, Y., Kim, D., …, & Nam, J. H. (2023). mRNA‐HPV vaccine encoding E6 and E7 improves therapeutic potential for HPV‐mediated cancers via subcutaneous immunization. Journal of Medical Virology. https://doi.org/10.1002/jmv.29309

Vancouver

Lee S, Yoon H, Hong SH, Kwon SP, Hong JJ, Kwak HW, et al. mRNA‐HPV vaccine encoding E6 and E7 improves therapeutic potential for HPV‐mediated cancers via subcutaneous immunization. Journal of Medical Virology. 2023. doi:10.1002/jmv.29309

BibTeX
@article{Lee2023,
  author = {Lee, Seonghyun and Yoon, Hyunho and Hong, Seol Hee and Kwon, Sung Pil and Hong, Jung Joo and Kwak, Hye Won and Park, Hyeong-Jun and Yoo, Soyeon and Bae, Seo-Hyeon and Park, Hyo-Jung and Lee, Jisun and Bang, Yoo-Jin and Lee, Yu-Sun and Kim, Jae-Yong and Yoon, Subin and Roh, Gahyun and Cho, Youngran and Kim, Yongkwan and Kim, Daegeun and Park, Sang-In and Kim, Do-Hyung and Lee, Sowon and Oh, Ayoung and Ha, Dahyeon and Lee, Soo-Yeon and Park, Misung and Hwang, Eun-Ha and Bae, Gyuseo and Jeon, Eunsu and Park, Sung Hyun and Choi, Won Seok and Oh, Ho Rim and Kim, In Woo and Youn, Hyewon and Keum, Gyochang and Bang, Eun-Kyoung and Rhee, Joon Haeng and Lee, Shee Eun and Nam, Jae-Hwan},
  title = {mRNA‐HPV vaccine encoding E6 and E7 improves therapeutic potential for HPV‐mediated cancers via subcutaneous immunization},
  journal = {Journal of Medical Virology},
  year = {2023},
  doi = {10.1002/jmv.29309}
}
Kostenlos starten →